Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth

Neoplasia

Volumn 7, Issue 3, 2005, Pages 241-252

  Bindukumar, B ^a,b   Schwartz, Stanley A ^b   Nair, Madhavan P N ^b   Aalinkeel, Ravikumar ^b   Kawinski, Elzbieta ^a   Chadha, Kailash C ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Angiogenic growth factors; f MRI; Gene array; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; UROKINASE; VASCULOTROPIN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; COLUMN CHROMATOGRAPHY; COMPLEX FORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC REGULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE TUMOR; SEMINAL PLASMA; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE;

EID: 15744392131     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04529     Document Type: Article

References (66)

1. ACS (2004). Cancer Figures and Facts 2004, American Cancer Society, Atlanta, GA.
2. Diamandis EP (1998). Prostate-specific antigen: its usefulness in clinical medicine. Trends Endocrinol Metab 9, 310-316.
3. Armbruster DA (1993). Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 39, 181-195.
4. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, and Stenman UH (1999). Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem 45, 814-821.
5. Lilja H, Oldbring J, Rannevik G, and Laurell CB (1987). Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 80, 281-285.
6. Clements J and Mukhtar A (1994). Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 78, 1536-1539.
7. Diamandis EP (1995). New diagnostic applications and physiological functions of prostate-specific antigen. Scand J Clin Lab Invest Suppl 221, 105-112.
8. Hautmann S, Huland E, Grupp C, Haese A, and Huland H (2000). Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer. Anticancer Res 20, 2151-2154.
9. Pummer K, Wirnsberger G, Purstner P, Stettner H, and Wandschneider G (1992). False positive prostate-specific antigen values in the sera of women with renal cell carcinoma. J Urol 148, 21-23.
10. Kucera E, Kainz C, Tempfer C, Zeillinger R, Koelbl H, and Sliutz G (1997). Prostate-specific antigen (PSA) in breast and ovarian cancer. Anticancer Res 17, 4735-4737.
11. Zarghami N, Grass L, Sauter ER, and Diamandis EP (1997). Prostate-specific antigen in serum during the menstrual cycle. Clin Chem 43, 1862-1867.
12. Folkman J, Watson K, Ingber D, and Hanahan D (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61.
13. Folkman J and Shing Y (1992). Angiogenesis. J Biol Chem 267, 10931-10934.
14. Fortier AH, Nelson BJ, Grella DK, and Holaday JW (1999). Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 91, 1635-1640.
15. Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J, Vu H, Plum SM, and Nelson BJ (2003). Recombinant prostate-specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 56, 212-219.
16. Pretlow TG, Pretlow TP, Yang B, Kaetzel CS, Delmoro CM, Kamis SM, Bodner DR, Kursh E, Resnick MI, and Bradley EL Jr (1991). Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer 49, 645-649.
17. Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, and Diamandis EP (2000). Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56, 527-532.
18. Stege R, Grande M, Carlstrom K, Tribukait B, and Pousette A (2000). Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 6, 160-165.
19. Balbay MD, Juang P, Ilansa N, Williams SD, Fidler IJ, et al. (1999). Stable transfection of human prostate cancer cell line PC-3 with prostate-specific antigen induced apoptosis both in vivo and in vitro. Proc Am Assoc Cancer Res 49, 225-228(Abstract).
20. Yu H, Levesque MA, Clark GM, and Diamandis EP (1998). Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 4, 1489-1497.
21. Rosser CJ, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee AK, and Pisters LL (2002). Prostate-specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 168, 2001-2005.
22. Papadopoulos I, Sivridis E, Giatromanolaki A, and Koukourakis MI (2001). Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res 7, 1533-1538.
23. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, and Kontermann RE (1999). Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 81, 1269-1273.
24. Sun XY, Donald SP, and Phang JM (2001). Testosterone and prostate-specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 22, 1775-1780.
25. Polyak K, Xia Y, Zweier JL, Kinzler KW, and Vogelstein B (1997). A model for p53-induced apoptosis. Nature 389, 300-305.
26. Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP, and Schwartz SA (2004). Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 64, 5311-5321.
27. Bull JH, Ellison G, Patel A, Muir G, Walker M, Underwood M, Khan F, and Paskins L (2001). Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 84, 1512-1519.
28. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, and Chinnaiyan AM (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826.
29. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, and Isaacs WB (2001). Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61, 4683-4688.
30. Bindukumar B, Kawinski E, Cherrin C, Gambino ML, Nair PM, Schwartz SA, Chadha KC. Two step procedure for purification of enzymatically active Prostate-specific antigen from seminal plasma. J Chromatogr B, in press.
31. Kawinski E, Levine E, and Chadha K (2002). Thiophilic interaction chromatography facilitates detection of various molecular complexes of prostate-specific antigen in biological fluids. Prostate 50, 145-153.
32. Chadha KC, Kawinski E, and Sulkowski E (2001). Thiophilic interaction chromatography of prostate-specific antigen. J Chromatogr B Biomed Sci Appl 754, 521-525.
33. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, and Isaacs JT (1997). Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 57, 4924-4930.
34. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, and Fidler IJ (1996). Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2, 1627-1636.
35. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, and Fidler IJ (1992). Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 84, 951-957.
36. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, and Murphy GP (1983). LNCaP model of human prostatic carcinoma. Cancer Res 43, 1809-1818.
37. Chomczynski P and Sacchi N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162, 156-159.
38. Mahajan SD, Schwartz SA, and Nair MP (2003). Immunological assays for chemokine detection in in vitro culture of CNS cells. Biol Proc Online 5, 90-102.
39. Sensabaugh GF and Blake ET (1990). Seminal plasma protein p30: simplified purification and evidence for identity with prostate-specific antigen. J Urol 144, 1523-1526.
40. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, and Kinch MS (1999). Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41, 275-280.
41. Hollas W, Hoosein N, Chung LW, Mazar A, Henkin J, Kariko K, Barnathan ES, and Boyd D (1992). Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb Haemost 68, 662-666.
42. Vassalli JD and Pepper MS (1994). Tumour biology. Membrane proteases in focus. Nature 370, 14-15.
43. Brigstock DR (2002). Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 5, 153-165.
44. Xin H, Curry J, Johnstone RW, Nickoloff BJ, and Choubey D (2003). Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. Oncogene 22, 4831-4840.
45. Wu M, Mazurchuk R, Chaudhary ND, Spernyak J, Veith J, Pera P, Greco W, Hoffman RM, Kobayashi T, and Bernacki RJ (2003). High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy- beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model. Cancer Res 63, 2477-2482.
46. Ustach CV, Taube ME, Hurst NJ Jr, Bhagat S, Bonfil RD, Chel ML, Schuger L, and Kim HR (2004). A potential oncogenic activity of platelet-derived growth factor D in prostate cancer progression. Cancer Res 64, 1722-1729.
47. Cohen P, Peehl DM, Lamson G, and Rosenfeld RG (1991). Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73, 401-407.
48. Lopez JB, Sahabudin RM, and Chin LP (2004). Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer? Int J Biol Markers 19, 164-167.
49. Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH, Roobol MJ, Pols HA, Lamberts SW, and Schroder FH (2004). Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab 89, 4391-4396.
50. Diamandis EP (2000). Prostate-specific antigen: a cancer fighter and a valuable messenger? Clin Chem 46, 896-900.
51. Nicholson B and Theodorescu D (2004). Angiogenesis and prostate cancer tumor growth. J Cell Biochem 91, 125-150.
52. Pakneshan P, Xing RH, and Rabbani SA (2003). Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J 17, 1081-1088.
53. Gallicchio MA, Kaun C, Wojta J, Binder B, and Bach LA (2003). Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. J Cell Physiol 197, 131-138.
54. Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA, Reed JC, and Fisher PB (2003). Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 22, 8758-8773.
55. Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, and Lopez-Otin C (1994). Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269, 16766-16773.
56. Hurlin PJ, Queva C, Koskinen PJ, Steingrimsson E, Ayer DE, Copeland NG, Jenkins NA, and Eisenman RN (1996). Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J 15, 2030.
57. Patarca R (1996). Protein phosphorylation and dephosphorylation in physiologic and oncologic processes. Crit Rev Oncogen 7, 343-432.
58. Kondapaka BS and Reddy KB (1996). Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer. Mol Cell Endocrinol 117, 53-58.
59. Lindberg RA and Hunter T (1990). cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol 10, 6316-6324.
60. Rosenberg IM, Goke M, Kanai M, Reinecker HC, and Podolsky DK (1997). Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol 273, G824-G832.
61. Xie D, Yin D, Tong X, Kelly O'J, Mori A, Miller C, Black K, Gui D, Said JW, and Koeffler HP (2004). Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 64, 1987-1996.
62. Farrar MA and Schreiber RD (1993). The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11, 571-611.
63. Dighe AS, Richards E, Old LJ, and Schreiber RD (1994). Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1, 447-456.
64. Dixon SC, Kruger EA, Bauer KS, and Figg WD (1999). Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemother Pharmacol Suppl 43, S78-S84.
65. Torriglia A, Perani P, Brossas JY, Altairac S, Zeggai S, Martin E, Treton J, Courtois Y, and Counis MF (1999). A caspase-independent cell clearance program. (2000) The LEI/L-DNase II pathway. Ann NY Acad Sci 926, 192-203.
66. Watt KW, Lee PJ, M'Timkulu T, Chan WP, and Loor R (1986). Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83, 3166-3170.